Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 318, Issue 19, 2017, Pages 1891-1902

  Greenbaum, C ^a   Atkinson, M ^b   Baidal, D ^c   Battaglia, M ^d   Becker, D ^e   Bingley, P ^f   Bosi, E ^d   Buckner, J ^a   Clements, M ^g   Colman, P ^h   DiMeglio, L ⁱ   Evans Molina, C ⁱ   Gitelman, S ^j   Goland, R ^k   Gottlieb, P ^l   Herold, K ^m   Knip, M ⁿ   Krischer, J ^o   Lernmark, A ^p   Moore, W ^g   Moran, A ^q   Muir, A ^r   Palmer, J ^s   Peakman, M ^t   Philipson, L ^u   Raskin, P ^v   Redondo, M ^w   Rodriguez, H ^o   Russell, W ^x   Spain, L ^y   Schatz, D A ^b   Sosenko, J ^c   Wherrett, D ^z   Wilson, D ^aa   Winter, W ^b   Ziegler, A ^ab   more..

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

^g Childrens Mercy Hospital Division of Clinical Genetics   (United States)

^h WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

ⁱ INDIANA UNIVERSITY   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k Columbia University ^*  (United States)

^l UNIVERSITY OF COLORADO DENVER   (United States)

^m YALE UNIVERSITY   (United States)

ⁿ UNIVERSITY OF HELSINKI   (Finland)

^o UNIVERSITY OF SOUTH FLORIDA   (United States)

^p Skane University   (Sweden)

^q UNIVERSITY OF MINNESOTA   (United States)

^r EMORY UNIVERSITY   (United States)

^s UNIVERSITY OF WASHINGTON   (United States)

^t KING'S COLLEGE LONDON   (United Kingdom)

^u UNIVERSITY OF CHICAGO   (United States)

^v University of Texas Southwestern   (United States)

^w BAYLOR UNIVERSITY   (United States)

^x VANDERBILT UNIVERSITY   (United States)

^y NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^z UNIVERSITY OF TORONTO   (Canada)

^aa STANFORD UNIVERSITY   (United States)

^ab Forschergruppe Diabetes   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; INSULIN; INSULIN ANTIBODY; PLACEBO; ANTIDIABETIC AGENT;

ADOLESCENT; ADULT; ARTICLE; AUSTRALIA; CANADA; CAUCASIAN; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FINLAND; FOLLOW UP; GERMANY; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INTRAVENOUS GLUCOSE TOLERANCE TEST; ITALY; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELATIVE; RISK FACTOR; SIBLING; SINGLE DRUG DOSE; SWEDEN; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; BLOOD; CLINICAL TRIAL; FAMILY; GENETICS; GLUCOSE TOLERANCE TEST; IMMUNOLOGY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ADOLESCENT; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FAMILY; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; TREATMENT FAILURE;

EID: 85036515544     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.17070     Document Type: Article

References (25)

1. Diabetes Prevention Trial—Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346 (22):1685-1691.
2. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial—Type 1. Diabetes Care. 2005;28(5):1068-1076.
3. Williams AJK, Bingley PJ, Bonifacio E, Palmer JP, Gale EAM. A novel micro-assay for insulin autoantibodies. J Autoimmun. 1997;10(5):473-478.
4. Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab. 2010;95 (1):25-33.
5. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al; TrialNet Natural History Committee; Type 1 Diabetes TrialNet Study Group. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes. 2009;10(2):97-104.
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(suppl 1):S62-S69.
7. Therneau TMGP. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer; 2000.
8. Gordon Lan KK, Demets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70 (3):659-663.
9. Lachin JM. Maximum information designs. Clin Trials. 2005;2(5):453-464.
10. Chaillous L, Lefèvre H, Thivolet C, et al; Diabète Insuline Orale group. Oral insulin administration and residual β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Lancet. 2000;356(9229):545-549.
11. Bonifacio E, Ziegler AG, Klingensmith G, et al; Pre-POINT Study Group. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA. 2015;313(15):1541-1549.
12. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974.
13. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala). J Clin Invest. 2003;111(3):409-418.
14. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54(6):1763-1769.
15. Herold KC, Gitelman SE, Ehlers MR, et al; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62(11):3766-3774.
16. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346(22): 1692-1698.
17. Sherry N, Hagopian W, Ludvigsson J, et al; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011;378(9790):487-497.
18. Hagopian W, Ferry RJ Jr, Sherry N, et al; Protégé Trial Investigators. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013;62(11):3901-3908.
19. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352(25):2598-2608.
20. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143-2152.
21. Pescovitz MD, Greenbaum CJ, Bundy B, et al; Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care. 2014;37 (2):453-459.
22. Orban T, Bundy B, Becker DJ, et al; Type 1 Diabetes TrialNet Abatacept Study Group. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care. 2014;37(4):1069-1075.
23. Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125(8):3285-3296.
24. Nathan DM, Genuth S, Lachin J, et al; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
25. Nathan DM; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9-16.